Aino Telaranta-Keerie

机构：AstraZeneca (United Kingdom) · ORCID：0009-0004-7899-839X

发表论文 12 篇 · 总被引 340 次 · h-index 6

代表论文

• Comparison of Targeted Next‐Generation Sequencing (NGS) and Real‐Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of Non‐Small Cell Lung Carcinoma—Superiority of NGS (2013 · Genes Chromosomes and Cancer · 被引 162)
• Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints (2010 · Scandinavian Journal of Gastroenterology · 被引 69)
• Targeted Resequencing RevealsALKFusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods (2013 · BioMed Research International · 被引 49)
• Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients (2014 · Journal of Thoracic Oncology · 被引 25)
• SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC). (2022 · Journal of Clinical Oncology · 被引 15)
• Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic (2023 · Journal of Molecular Diagnostics · 被引 10)